Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
Illegal activities are a significant clinical problem in individuals with Huntington’s disease, highlighting the need for improved screening measures and protocols to guide patient management.
Neurologic complications are common in children hospitalized with influenza, especially those with chronic neurologic conditions, and are associated with worse outcomes.
Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.
Vanderbilt University Medical Center has received a $31.7 million federal grant to harmonize research data gathered on human subjects in scores of disparate studies of Alzheimer’s disease and related dementias.